Cerus Corp CERS
We take great care to ensure that the data presented and summarized in this overview for CERUS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CERS
View all-
Baker Bros. Advisors LP New York, NY19.5MShares$32.5 Million0.36% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl18.2MShares$30.4 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.9MShares$23.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$18.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA8.54MShares$14.3 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT7.33MShares$12.2 Million0.06% of portfolio
-
Nikko Asset Management Americas, Inc.7.04MShares$11.8 Million0.14% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.7.04MShares$11.8 Million0.01% of portfolio
-
Senvest Management, LLC New York, NY6.01MShares$10 Million0.37% of portfolio
-
Geode Capital Management, LLC Boston, MA4.42MShares$7.37 Million0.0% of portfolio
Latest Institutional Activity in CERS
Top Purchases
Top Sells
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Insider Transactions at CERS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 04
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
54,272
-9.19%
|
$108,544
$2.15 P/Share
|
Sep 03
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
28,385
-4.59%
|
$56,770
$2.18 P/Share
|
Aug 15
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
16,667
-3.4%
|
$33,334
$2.06 P/Share
|
Aug 02
2024
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,605
-4.7%
|
$43,210
$2.5 P/Share
|
Jul 01
2024
|
Dean A. Gregory |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
Jun 05
2024
|
Gail Schulze Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.66%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Hua Shan Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+35.59%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Daniel N Swisher Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+21.39%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Frank Witney Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+15.38%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Ann Lucena Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+26.27%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Timothy L. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+21.61%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Jami K Nachtsheim Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+21.24%
|
$200,000
$5.0 P/Share
|
Jun 05
2024
|
Eric Bjerkholt Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+18.01%
|
$200,000
$5.0 P/Share
|
May 13
2024
|
Hua Shan Director |
BUY
Open market or private purchase
|
Direct |
2,500
+7.17%
|
$2,500
$1.99 P/Share
|
May 10
2024
|
Jami K Nachtsheim Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.81%
|
$2,000
$1.79 P/Share
|
May 09
2024
|
Frank Witney Director |
BUY
Open market or private purchase
|
Direct |
20,000
+10.0%
|
$20,000
$1.89 P/Share
|
May 09
2024
|
Daniel N Swisher Jr Director |
BUY
Open market or private purchase
|
Direct |
2,500
+2.28%
|
$2,500
$1.88 P/Share
|
Mar 14
2024
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,497
-3.36%
|
$21,497
$1.97 P/Share
|
Mar 14
2024
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,824
-3.5%
|
$17,824
$1.97 P/Share
|
Mar 14
2024
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
63,611
-1.96%
|
$127,222
$2.02 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.88M shares |
---|---|
Open market or private purchase | 37K shares |
Exercise of conversion of derivative security | 173K shares |
Open market or private sale | 491K shares |
---|